AVADO — Final Overall Survival Results of First-Line Docetaxel in Combination with Escalating Doses of Bevacizumab for HER2-Negative Metastatic Breast Cancer

Presentation discussed in this issue:

Miles DW et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, Phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). San Antonio Breast Cancer Symposium 2009;<u>Abstract 41</u>.

Editor's comment: At the end of this slide set are several graphics with results from a recent Patterns of Care study of 100 US-based medical oncologists.

Slides from a presentation at SABCS 2009

Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC)


Miles DW et al. SABCS 2009;Abstract 41.

> Research To Practice®



- Three Phase III trials (AVADO¹, ECOG-2100², and RIBBON-1³) have reported positive results with bevacizumab (BV) in the first-line mBC setting (¹ASCO 2008;LBA1011, ²NEJM 2007;357:2666, ³ASCO 2009;1005).
- AVADO demonstrated significantly improved progressionfree survival (PFS) with BV plus docetaxel (D) at 10 months follow-up.
 - Median PFS: 8.7 mos (7.5 mg/kg BV + D), 8.8 mos (15 mg/kg BV + D), and 8.0 mos (D + placebo).
- Final overall survival (OS) and updated results of other study endpoints at 25 months follow-up are presented in the current analysis from the AVADO study.


Source: Miles DW et al. SABCS 2009; Abstract 41.




Research

To Practice®

Updated PFS Analysis (Bev 7.5 mg/kg dose)





For more visit ResearchToPractice.com/5MJCBreast

Updated Efficacy Analysis

	BV, 7.5 mg/kg + docetaxel (n = 248)	BV, 15 mg/kg + docetaxel (n = 247)	Placebo + docetaxel (n = 241)
Median PFS	9.0 mos	10.0 mos	8.1 mos
HR (vs placebo)	0.80*	0.67*	
<i>p</i> -value (vs placebo)	0.0450†	0.0002†	-
Median OS	30.8 mos	30.2 mos	31.9 mos
HR (vs placebo)	1.05	1.03	—
<i>p</i> -value (vs placebo)	0.7198†	0.8528†	:. <u></u>
*Stratified; + p values are of expl	oratory nature.		1
Source: Miles DW et al. SABCS	2009;Abstract 41.		Research To Pract

Updated Efficacy Analysis (continued)

Patients with measurable disease at baseline	BV, 7.5 mg/kg + docetaxel (n = 201)	BV, 15 mg/kg + docetaxel (n = 206)	Placebo + docetaxel (n = 207)
Overall response rate (ORR) <i>p</i> -value (vs control) [†]	55.2% 0.0739	64.1% 0.0003	46.4% —
Intent to treat population	(n = 248)	(n = 247)	(n = 241)
1-year survival rate <i>p</i> -value (vs control) [†]	81% 0.198	84% 0.02	76% —
Patients still at risk (n)	195	201	178
+ p values are of exploratory nature.			Research

Source: Miles DW et al. SABCS 2009; Abstract 41.

Research **To Practice®**

Select Adverse Events > Grade 3

	Bev, 7.5 mg/kg + docetaxel (n = 252)	Bev, 15 mg/kg + docetaxel (n = 247)	Placebo + docetaxel (n = 231)
Febrile neutropenia (%)	15.1	16.6	11.7
Hypertension (%)	0.8	4.5	1.3
Bleeding (%)	1.2	1.2	0.9
Wound-healing complications (%)	0.4	0.4	0.9
Venous thromboembolic events (%)	1.6	1.2	3.5
GI perforation (%)	0.4	0.4	0.9

Source: Miles DW et al. SABCS 2009; Abstract 41.

Research To Practice®


Conclusions

- First-line BV (15 mg/kg) plus docetaxel significantly improves PFS and overall response rate compared to docetaxel alone in patients with HER2- mBC.
 - PFS: 10.0 mos vs 8.1 mos
 - ORR: 64.1% vs 46.4%
- Addition of increasing doses of BV to docetaxel therapy has a limited impact on the existing docetaxel safety profile.
- No difference in OS was observed between the study arms.
- Exploratory analysis in patients receiving post-progression treatment suggests that the use of 2nd-line BV with chemotherapy may influence OS (data not shown).

Source: Miles DW et al. SABCS 2009; Abstract 41.


Research To Practice®

A 45-year-old responds to 1st-line paclitaxel and bevacizumab for mBC. Paclitaxel is discontinued due to toxicity.



A 75-year-old with node+ trip neg BC presents with symptomatic metastases after completion of AC \rightarrow T 2 years ago.

What would you likely recommend if patient is not eligible for a clinical trial? (Check all that apply)



For more visit ResearchToPractice.com/5MJCBreast